Solid Biosciences to raise $240 mln in private funding, shares rise

Solid Biosciences

06/03/2026 13:46

** Shares of genetic-muscle disorder drug developer Solid Biosciences SLDB.O rise 14.26% to $6.43 premarket

**  Company says it will raise about $240 mln in a private funding round to support research and operations

**  Says it will sell nearly 15 mln shares at $5.61 each and issue warrants for up to 28 mln more shares

**  Investors in the round include Perceptive Advisors, Bain Capital Life Sciences, RA Capital and others - SLDB

**  Company says proceeds will fund gene therapy programs for Duchenne muscular dystrophy, a muscle-wasting disease

** Shares up 41% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))